Kymera Therapeutics (KYMR) Leases: 2019-2025
Historic Leases for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $42.9 million.
- Kymera Therapeutics' Leases fell 10.65% to $42.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year decrease of 10.65%. This contributed to the annual value of $47.4 million for FY2024, which is 10.46% down from last year.
- According to the latest figures from Q3 2025, Kymera Therapeutics' Leases is $42.9 million, which was down 6.73% from $46.0 million recorded in Q2 2025.
- Over the past 5 years, Kymera Therapeutics' Leases peaked at $56.6 million during Q1 2023, and registered a low of $8.9 million during Q4 2022.
- For the 3-year period, Kymera Therapeutics' Leases averaged around $49.9 million, with its median value being $48.7 million (2024).
- Its Leases has fluctuated over the past 5 years, first surged by 508.19% in 2023, then decreased by 12.85% in 2024.
- Kymera Therapeutics' Leases (Quarterly) stood at $9.4 million in 2021, then fell by 5.48% to $8.9 million in 2022, then spiked by 494.29% to $52.9 million in 2023, then decreased by 10.46% to $47.4 million in 2024, then fell by 10.65% to $42.9 million in 2025.
- Its Leases stands at $42.9 million for Q3 2025, versus $46.0 million for Q2 2025 and $46.7 million for Q1 2025.